Company news

Sensei Biotherapeutics, Inc. news in 2023

Sensei Biotherapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

November 6, 2023

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

November 2, 2023

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

October 31, 2023

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

October 24, 2023

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

October 22, 2023

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®

September 26, 2023

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

September 20, 2023

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Im...

September 12, 2023

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

August 29, 2023

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 2, 2023

Sensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth Conference

August 1, 2023

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors”

June 12, 2023

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

May 31, 2023

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 8, 2023

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

April 19, 2023

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

April 17, 2023

Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium

March 29, 2023

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

March 27, 2023

Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

March 20, 2023

Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023

March 13, 2023

Sensei Biotherapeutics Adopts Stockholder Rights Agreement

March 6, 2023

Sensei Biotherapeutics to Participate in Oppenheimer’s 33rd Annual Healthcare Conference

March 5, 2023

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

February 20, 2023

Sensei Biotherapeutics to Participate in Citi’s 2023 Virtual Oncology Leadership Summit

February 15, 2023

Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

February 13, 2023

Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody

February 5, 2023

Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors

January 4, 2023

Decks in 2023